Major factors for the growth of the market are increasing use of SPECT and PET analysis in radiopharmaceuticals, increased awareness of people for radiopharmaceuticals, and ready availability of radiopharmaceuticals. Novel applications such as Alzheimers and continually expanding oncology application segment also drive the market. However, some of the major constrains of the market are complex FDA toxicology and other regulatory requirements, lack of specific guidelines from the FDA for good manufacturing practices of radiopharmaceuticals, lack of consensus for standardized image acquisition in nuclear imaging procedures.
Therapeutic nuclear medicine finds its application in treatment of various types of cancer such as lymphoma, bone metastasis, thyroid, endocrine tumors etc. Radionuclide therapy has unique promise as a vehicle for personalized treatment of cancer. Alpha emitters which use bismuth-213 and astatine-211 labeled monoclonal antibodies in patients with leukemia and brain tumor and radium- 223 are being evaluated in breast and prostate cancer patients with bone metastases. Beta- Emitters are currently limited to four beta emitters, yttrium-90 and iodine-131 which are used in treatment of non-Hodgkins lymphoma, samarium-153-EDTMP and strontium-89-chloride for palliation of bone metastases. The market scope of preclinical and clinical research in the therapy field is much broader.
The number of therapeutic procedures in North America, Europe and Asia-Pacific are 265, 22195, and 271248 for the year 2013 respectively. Talking about country wise therapeutic procedures, US have 262 therapeutic procedures. Developing countries like India hold strong market potential accounting for 7475 therapeutic procedures.
Market is segmented by Beta Emitters (Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (SM-153), Rhenium-186 (RE-186), Lutetium-177 (LU-177)and Others) Alpha emitters(Radium-223 (RA-223) & Alpharadin, Actinium-225 (AC-225), Lead-212 (PB-212)/Bismuth-212 (BI-212)and Astatine-211 (AT-211)) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103 and Iridium-192), by applications and by geography ( North America, Europe and Asia-Pacific).
Major players in the market are Mallinckrodt, Lantheus medical imaging, IBA Group, Traid Isotope, Siemens Healthcare etc. Mergers and acquisitions of small and medium sized manufacturers to enter in overseas market is another strategy adopted by multinational players.
What the Report Offers
1)Market Definition Global nuclear medicine Therapeutic (Alpha Emitters, Beta Emitters and Brachytherapy) Market along with identification of key drivers and restraints for the market.
2)Market analysis for the Global nuclear medicine Therapeutic (Alpha Emitters, Beta Emitters and Brachytherapy) with region specific assessments and competition analysis on a global and regional scale.
3)Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
4)Extensively researched competitive landscape section with profiles of major companies along with their share of markets.
5) A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
Reasons for Buying this Report
1)For gaining an exhaustive understanding of the worldwide market for Global nuclear medicine Therapeutic (Alpha Emitters, Beta Emitters and Brachytherapy) . Would be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
2)An ideal opportunity for industry consultants and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
3) Wide-ranging information provided about the leading market players and the major strategies adopted by them
Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.3 Porter’s Five Forces
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Consumers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitute Products and Services
5.3.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing incidents of Cancer and Cardiac ailments
6.1.2 Increasing awareness of radiopharmaceuticals
6.1.3 Public Awareness
6.1.4 Ready availability of radiopharmaceuticals
6.2 Market Restraints
6.2.1 Shorter half-life of radiopharmaceuticals
6.2.2 High capital investment
6.2.3 Regulatory Guidelines
6.2.4 Reimbursement issues
7. Market Segmentation
7.1 Therapeutic Market
7.1.1 Beta Emitters
220.127.116.11 Iodine-131 (I-131)
18.104.22.168 Yttrium-90 (Y-90)
22.214.171.124 Samarium-153 (SM-153).
126.96.36.199 Rhenium-186 (RE-186)
188.8.131.52 Lutetium-177 (LU-177)
7.1.2 Alpha Emitters
184.108.40.206 Radium-223 (RA-223) & Alpharadin
220.127.116.11 Actinium-225 (AC-225)
18.104.22.168 Lead-212 (PB-212)/Bismuth-212 (BI-212)
22.214.171.124 Astatine-211 (AT-211)
126.96.36.199 Radium-224 (RA-224)
188.8.131.52 Thorium-227 (TH-227)
7.2 By Application
7.2.2 Bone Metastasis
7.2.4 Endocrine Tumors
8. Market Segmentation by Geography
8.1 North America
8.2.6 Spain & Portugal
8.3.5. South Korea
8.3.6. Australia & New Zealand
8.4. Middle East and North Africa (MENA)
8.5. Latin America
9.1 Merger and Acquisition Analysis
9.2 New Product Launches
9.3 Agreements, Collaborations & Partnerships
9.4 Patent Analysis
9.5 The Challengers
10. Key Vendor Analysis
10.1 IBA Group
10.2 Lantheus Medical Imaging
10.3 Triad Isotopes
10.4 Siemens Healthcare (PETNET Solutions)
10.5 NTP Radioisotopes
11. Analyst Outlook for Investment Opportunities
12. Future Outlook of the Market